BSX:NYE-Boston Scientific Corporation

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 42.45

Change

+0.20 (+0.47)%

Market Cap

USD 28.38B

Volume

4.47M

Analyst Target

USD 43.72
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Boston Scientific Corp is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-07-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-3.31 (-3.03%)

USD 189.50B
SYK Stryker Corporation

-1.63 (-0.48%)

USD 133.55B
MDT Medtronic PLC

-0.17 (-0.21%)

USD 112.28B
EW Edwards Lifesciences Corp

-2.81 (-3.12%)

USD 55.80B
ZBH Zimmer Biomet Holdings Inc

-0.77 (-0.63%)

USD 26.16B
STE STERIS plc

+1.23 (+0.62%)

USD 21.09B
PHG Koninklijke Philips NV ADR

-0.18 (-0.89%)

USD 18.20B
SNN Smith & Nephew SNATS Inc

+0.12 (+0.50%)

USD 10.70B
BIO Bio-Rad Laboratories Inc

-1.89 (-0.65%)

USD 8.76B
PEN Penumbra Inc

-1.37 (-0.65%)

USD 8.60B

ETFs Containing BSX

EDOC:AU BetaShares Digital Health.. 9.34 % 0.00 %

N/A

N/A
UMDV:SW iShares US Medical Device.. 8.48 % 0.00 %

-0.05 (-0.34%)

USD 0.18B
GDOC Goldman Sachs ETF Trust 5.84 % 0.00 %

-0.19 (-0.34%)

USD 0.03B
IHI iShares U.S. Medical Devi.. 4.61 % 0.43 %

-0.78 (-0.34%)

USD 5.55B
EUPA:XETRA Ossiam Shiller Barclays C.. 4.53 % 0.00 %

+0.04 (+-0.34%)

USD 0.03B
EUPB:XETRA Ossiam Shiller Barclays C.. 4.53 % 0.00 %

-0.12 (-0.34%)

USD 0.03B
5OGE:PA Ossiam Shiller Barclays C.. 4.53 % 0.00 %

+0.36 (+-0.34%)

N/A
5OGE:SW Ossiam Shiller Barclays C.. 4.53 % 0.00 %

-0.10 (-0.34%)

USD 3.88M
5OGU:SW Ossiam Shiller Barclays C.. 4.53 % 0.00 %

N/A

USD 0.03B
XYLP:LSE Global X S&P 500® Covere.. 4.28 % 0.00 %

-0.04 (-0.34%)

USD 0.01B
XYLU:LSE Global X S&P 500® Covere.. 4.18 % 0.00 %

-0.05 (-0.34%)

USD 0.01B
MHCD:CA Middlefield Healthcare Di.. 4.00 % 0.00 %

-0.05 (-0.34%)

CAD 0.16B
DXQ:CA Dynamic Active Enhanced Y.. 3.19 % 0.00 %

-0.09 (-0.34%)

CAD 0.38B
BKUS 2.89 % 0.00 %

N/A

N/A
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.15 % 0.00 %

-0.09 (-0.34%)

USD 0.05B
MEDTE:PA BNP Paribas Easy ECPI Glo.. 2.15 % 0.00 %

-0.09 (-0.34%)

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.15 % 0.00 %

-0.01 (-0.34%)

N/A
BTHM BlackRock ETF Trust - Bla.. 2.00 % 0.00 %

-0.29 (-0.34%)

USD 6.84M
2B78:XETRA iShares Healthcare Innova.. 1.85 % 0.00 %

-0.08 (-0.34%)

USD 1.14B
2B78:F iShares Healthcare Innova.. 1.82 % 0.00 %

-0.08 (-0.34%)

N/A
XMLH:XETRA L&G Healthcare Breakthrou.. 1.76 % 0.00 %

-0.11 (-0.34%)

USD 0.07B
DOCG:LSE L&G Healthcare Breakthrou.. 1.76 % 0.00 %

-8.80 (-0.34%)

USD 0.08B
DOCT:LSE L&G Healthcare Breakthrou.. 1.76 % 0.00 %

-0.11 (-0.34%)

USD 0.08B
HEAL:SW iShares Healthcare Innova.. 1.72 % 0.00 %

-0.11 (-0.34%)

N/A
EQUL IndexIQ ETF Trust - IQ En.. 1.47 % 0.00 %

-0.05 (-0.34%)

USD 6.93M
WELP:LSE HAN-GINS Indxx Healthcare.. 1.25 % 0.00 %

-6.95 (-0.34%)

USD 0.02B
W311:XETRA HAN-GINS Indxx Healthcare.. 1.23 % 0.00 %

-0.09 (-0.34%)

USD 0.02B
LNGR 0.00 % 0.50 %

N/A

N/A
GDNA 0.00 % 0.00 %

N/A

N/A
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

-0.23 (-0.34%)

USD 0.06B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-6.88 (-0.34%)

USD 1.14B
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

-0.09 (-0.34%)

USD 1.14B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

-0.08 (-0.34%)

USD 0.02B
BSCU Invesco BulletShares 2030.. 0.00 % 0.00 %

+0.06 (+-0.34%)

USD 0.63B
AGNG Global X Aging Population.. 0.00 % 0.00 %

+0.01 (+-0.34%)

USD 0.06B
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.00 %

-0.13 (-0.34%)

CAD 0.07B
PLDR Putnam Sustainable Leader.. 0.00 % 0.00 %

-0.34 (-0.34%)

USD 0.53B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.12% 69% C- 70% C-
Dividend Return N/A N/A N/A N/A F
Total Return 20.12% 69% C- 67% D+
Trailing 12 Months  
Capital Gain 27.29% 71% C- 93% A
Dividend Return N/A N/A N/A N/A F
Total Return 27.29% 71% C- 92% A
Trailing 5 Years  
Capital Gain 230.35% 91% A- 98% N/A
Dividend Return N/A N/A N/A N/A F
Total Return 230.35% 91% A- 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 26.79% 79% B- 82% B
Dividend Return 26.79% 79% B- 81% B-
Total Return N/A N/A N/A N/A F
Risk Return Profile  
Volatility (Standard Deviation) 11.81% 86% B+ 82% B
Risk Adjusted Return 226.89% 100% F 100% F
Market Capitalization 28.38B 86% B+ 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 357.70 42% 20%
Price/Book Ratio 6.39 38% 16%
Price / Cash Flow Ratio 0.00 86% 73%
Price/Free Cash Flow Ratio 0.00 86% 67%
Management Effectiveness  
Return on Equity 22.10% 90% 87%
Return on Invested Capital N/A N/A N/A
Return on Assets 5.04% 76% 74%
Debt to Equity Ratio 54.97% 59% 60%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector